Research Paper Volume 16, Issue 19 pp 12769—12780

Bezafibrate mitigates cardiac injury against coronary microembolization by preventing activation of p38 MAPK/NF-κB signaling

class="figure-viewer-img"

Figure 6. The effects of Bezafibrate in the expression of Bax, Bcl-2, and cleaved caspase-3 in cardiac tissues of CME rats. (A) Representative images of western blot results of Bax, Bcl-2, and cleaved caspase-3; (B) Quantification of Bax, Bcl-2, and cleaved caspase-3 (n=12, **, p<0.01 vs. control group; #, ##, p<0.05, 0.01 vs. CME group).